The company reported a net loss of $33.2 million, which is less than the same period last year. During the past year, BioMimetic Therapeutics received FDA clearance on several orthopedic devices and has been working with the regulatory body to obtain approval for its Augment Bone Graft, which was cleared by the Australian Therapeutics Goods Administration during the fourth quarter of last year.
More recently, the company has announced clearance internationally and has made progress on studies for their products.
More Articles on Orthopedic Devices:
17 Spine Devices Receive FDA 510(k) Clearance in February
TranS1 Reports 32% Drop in 4Q Revenue
American Joint Replacement Registry Now Includes 19k Procedures
BioMimetic Reports 2011 RevenueWritten by Laura Miller | March 14, 2012
BioMimetic Therapeutics recently announced financial results for the fourth quarter of 2011, where it reported total revenue of $458,300, an increase over the same period last year.
© Copyright ASC COMMUNICATIONS 2011. Interested in LINKING to or REPRINTING this content? View our policies here.